Mani Foroohar
Stock Analyst at Leerink Partners
(1.99)
# 3,105
Out of 5,113 analysts
168
Total ratings
51.61%
Success rate
-0.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO | Maintains: Outperform | $16 → $20 | $13.79 | +45.03% | 11 | Dec 15, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $85 → $100 | $80.29 | +24.56% | 16 | Dec 15, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $75 → $86 | $77.87 | +10.44% | 16 | Dec 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Market Perform | $370 → $351 | $357.98 | -1.95% | 12 | Dec 15, 2025 | |
| MRNA Moderna | Maintains: Underperform | $15 → $18 | $48.71 | -63.05% | 19 | Nov 21, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $9 → $20 | $7.50 | +166.67% | 6 | Oct 7, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Market Perform | $9 → $7 | $3.72 | +88.17% | 13 | Oct 3, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $45 → $10 | $21.13 | -52.67% | 2 | Jul 21, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $4.73 | +26.85% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $7.96 | +239.20% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $72 | $18.27 | +294.09% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $4.01 | +323.94% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $94.29 | -48.03% | 11 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $13.47 | +63.33% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $12.49 | +4.08% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $16.42 | +76.61% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $12.17 | +154.72% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.73 | +858.51% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $67.05 | -40.34% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $14.63 | +474.16% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.16 | +224.07% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $31.56 | +143.98% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.16 | +16.28% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $55.52 | +36.89% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.53 | +2,122.22% | 4 | May 12, 2022 |
REGENXBIO
Dec 15, 2025
Maintains: Outperform
Price Target: $16 → $20
Current: $13.79
Upside: +45.03%
Ionis Pharmaceuticals
Dec 15, 2025
Maintains: Outperform
Price Target: $85 → $100
Current: $80.29
Upside: +24.56%
BridgeBio Pharma
Dec 15, 2025
Maintains: Outperform
Price Target: $75 → $86
Current: $77.87
Upside: +10.44%
Alnylam Pharmaceuticals
Dec 15, 2025
Maintains: Market Perform
Price Target: $370 → $351
Current: $357.98
Upside: -1.95%
Moderna
Nov 21, 2025
Maintains: Underperform
Price Target: $15 → $18
Current: $48.71
Upside: -63.05%
Lexeo Therapeutics
Oct 7, 2025
Maintains: Outperform
Price Target: $9 → $20
Current: $7.50
Upside: +166.67%
Rocket Pharmaceuticals
Oct 3, 2025
Maintains: Market Perform
Price Target: $9 → $7
Current: $3.72
Upside: +88.17%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $21.13
Upside: -52.67%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $4.73
Upside: +26.85%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $7.96
Upside: +239.20%
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $18.27
Upside: +294.09%
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $4.01
Upside: +323.94%
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $94.29
Upside: -48.03%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $13.47
Upside: +63.33%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $12.49
Upside: +4.08%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $16.42
Upside: +76.61%
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $12.17
Upside: +154.72%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.73
Upside: +858.51%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $67.05
Upside: -40.34%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $14.63
Upside: +474.16%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.16
Upside: +224.07%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $31.56
Upside: +143.98%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.16
Upside: +16.28%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $55.52
Upside: +36.89%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.53
Upside: +2,122.22%